Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder

被引:137
|
作者
Stampfer, DS [1 ]
Carpinito, GA
Rodriguez-Villanueva, J
Willsey, LW
Dinney, CP
Grossman, HB
Fritsche, HA
McDougal, WS
机构
[1] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA
[2] Boston Univ, Med Ctr, Dept Urol, Boston, MA 02215 USA
[3] Univ Texas, Md Anderson Canc Ctr, Dept Lab Sci, Houston, TX USA
[4] Univ Texas, Md Anderson Canc Ctr, Dept Urol, Houston, TX USA
来源
JOURNAL OF UROLOGY | 1998年 / 159卷 / 02期
关键词
bladder; carcinoma; transitional cell; bladder neoplasms; nuclear matrix; tumor markers; biological;
D O I
10.1016/S0022-5347(01)63930-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Urinary nuclear matrix protein (NMP22) was evaluated for detection of new and recurrent bladder tumors in patients with a history of transitional cell carcinoma. Our objective was to determine sensitivity and specificity of this marker for tumors of various stages and grades, as well as its use as an adjunct to or substitute for urinary cytology. Materials and Methods: A total of 231 patients with a history of transitional cell carcinoma provided 288 voided urine samples before cystoscopic examination at 1 of 3 institutions (53 patients were reevaluated at least once). Urine samples were assayed for NMP22 using the NMP22 Test Kit.dagger Select patients underwent biopsy with appropriate additional therapy. Voided urinary cytology was obtained in 200 cases. End points for determination of the absence and presence of tumor were negative cystoscopy and positive biopsy, respectively. A receiver operating characteristics curve was constructed to determine the optimal NMP22 threshold for detection of transitional cell carcinoma. For positive biopsies NMP22 values were also correlated with tumor stage and grade. Comparison to cytology was limited to patients with complete data. Results: There were 208 negative cystoscopies (158 with cytology) and 66 positive cystoscopies with biopsy (42 with cytology). Of the cases 14 were eliminated from statistical analysis due to incomplete data. Receiver operating characteristics curve interpretation determined that 6.4 units per mi. was an optimal reference value for detection of transitional cell carcinoma in this patient group. Sensitivity and specificity for all pathological groupings was 68 and 80%, respectively. When compared to cytology the sensitivities of NMP22 and cytology were 67 versus 31 or 40% (depending on the definition of positive cytology). Conclusions: NMP22 values represented significant improvement over urinary cytology for detection of transitional cell carcinoma. The sensitivity of NMP22 for detection of transitional cell carcinoma in bladder cancer patients was as much as twice that of cytology when a reference value of 6.4 units per mi. was used. NMP22 analysis was less costly than cytology and operator independent. While NMP22 has previously been shown to be a strong predictor of recurrence after tumor resection, it is an effective and sensitive screening test for detecting tumors in patients with transitional cell carcinoma.
引用
收藏
页码:394 / 398
页数:5
相关论文
共 50 条
  • [21] Detection of Recurrent Bladder Cancer NMP22 Test or Urine Cytology?
    Hosseini, Jalil
    Golshan, Ali Reza
    Mazloomfard, Mohammad Mohsen
    Mehrsai, Abdolrasoul
    Zargar, Mohammad Ali
    Ayati, Mohsen
    Shakeri, Saeed
    Jasemi, Majid
    Kabiri, Mahmoud
    UROLOGY JOURNAL, 2012, 9 (01) : 367 - 372
  • [22] DETECTION OF RECURRENT BLADDER CANCER NMP22 TEST OR URINE CYTOLOGY?
    Jalil, H.
    Alireza, G.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 258 - 258
  • [23] Evaluation of NMP22 in bladder cancer patients sensitive to environmental toxins
    Szymanska, Beata
    Pawlik, Krzysztof J.
    Sawicka, Ewa
    Dembowski, Janusz
    Kowal, Pawel
    Zdrojowy, Romuald
    Dlugosz, Anna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 26 (07): : 1069 - 1075
  • [24] Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder
    Mian, C
    Lodde, M
    Haitel, A
    Vigl, EE
    Marberger, M
    Pycha, A
    UROLOGY, 2000, 55 (02) : 223 - 226
  • [25] Role of NMP22 Bladder Check Test in Early Detection of Bladder Cancer with Recurrence
    Kundal, Vijay K.
    Pandith, Arshad A.
    Hamid, Arif
    Shah, Azra
    Kundal, Rakhsha
    Wani, Saleem M.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (05) : 1279 - 1282
  • [26] Urinary BTA-Stat, BTA-Trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder
    Serretta, V
    Pomara, G
    Rizzo, I
    Esposito, E
    EUROPEAN UROLOGY, 2000, 38 (04) : 419 - 424
  • [27] NMP22 TEST VERSUS URINE CYTOLOGY IN DETECTION OF RECURRENT BLADDER CANCER
    Hosseini, J.
    Golshan, A. R.
    Mazloomfard, M. M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 594 - 594
  • [28] Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer
    Grocela, JA
    McDougal, WS
    UROLOGIC CLINICS OF NORTH AMERICA, 2000, 27 (01) : 47 - +
  • [29] The role of NMP22 in the detection of persistent urothelial cancer of the bladder in Chinese population
    Chau, Ming
    Chen, Haige
    Wang, Aiguo
    Zhang, Zhensheng
    Xu, Chuanliang
    Li, Wen
    Jun, Tian
    Li, Changling
    Yan, Ming
    Li, Ming
    Xue, Wei
    Huang, Yiran
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A305 - A306
  • [30] NMP22 and surveillance for recurrent bladder cancer - In reply
    Grossman, HB
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 45 - 46